FGFR2 Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Bladder Urothelial Carcinoma1
FGFR2::? Fusion	Erdafitinib	Predictive	C	Supports Sensitivity Response	3	submitted	EID10404 Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC) PMID 31088831 · Bahleda et al., 2019 · Open in CIViC	civic
Cholangiocarcinoma6
FGFR2 Amplification AND FGFR2::? Fusion	Futibatinib	Predictive	C	Supports Sensitivity Response	1	submitted	EID11642 In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Bladder Urothelial Carcinoma1

FGFR2::? Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

submitted

EID10404

Phase I dose-escalation cohort of patients with advanced solid tumors in which antineoplastic therapy (NCT01703481) was no longer effective using pan-FGFR inhibitor JNJ-42756493. Among 2 urothelial ca… (full text at CIViC)

PMID 31088831 · Bahleda et al., 2019 · Open in CIViC

civic

Cholangiocarcinoma6

FGFR2 Amplification AND FGFR2::? Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11642

In a phase 1 multihistology trial of the FGFR1/2/3/4 inhibitor futibatinib, an objective response rate of 13.7% was seen with responses in a broad spectrum of tumors and across a broad spectrum of FGF… (full text at CIViC)

Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma1
FGFR2::v Fusion OR FGFR2::? Fusion	Pemigatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID8173 In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC) PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC	civic

Cholangiolocellular Small Duct Intrahepatic Cholangiocarcinoma1

FGFR2::v Fusion OR FGFR2::? Fusion

Pemigatinib

Predictive

Supports Sensitivity Response

accepted

EID8173

In a multicentre, open-label, single-arm, phase 2 study (FIGHT-202), patients with disease progression following at least one previous treatment received a starting dose of 13·5 mg oral pemigatinib on… (full text at CIViC)

PMID 32203698 · Abou-Alfa et al., 2020 · Open in CIViC

civic

Intrahepatic Cholangiocarcinoma3
FGFR2::v Fusion OR FGFR2::? Fusion	Derazantinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID7329 Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC) PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC	civic
FGFR2::v Fusion OR FGFR2::? Fusion	Futibatinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11609 In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic
FGFR2::v Fusion OR FGFR2::? Fusion	Futibatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11612 In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC) PMID 36652354 · Goyal et al., 2023 · Open in CIViC	civic

Intrahepatic Cholangiocarcinoma3

FGFR2::v Fusion OR FGFR2::? Fusion

Derazantinib

Predictive

Supports Sensitivity Response

accepted

EID7329

Actionable fibroblast growth factor receptor 2 (FGFR2) fusions have been identified in intrahepatic cholangiocarcinomas (iCCA). Derazantinib, a multi-kinase inhibitor with potent pan-FGFR activity sho… (full text at CIViC)

PMID 30420614 · Mazzaferro et al., 2019 · Open in CIViC

civic

FGFR2::v Fusion OR FGFR2::? Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11609

In the phase 2 trial (NCT02052778), 103 patients (22-79 years of age) with unresectable or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements were treated with the … (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

civic

FGFR2::v Fusion OR FGFR2::? Fusion

Futibatinib

Predictive

Supports Sensitivity Response

submitted

EID11612

In a phase 2 trial (NCT02052778) of the FGFR1/2/3/4 inhibitor futibatinib in 103 patients with previously treated intrahepatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements, the overal… (full text at CIViC)

PMID 36652354 · Goyal et al., 2023 · Open in CIViC

civic

Transitional Cell Carcinoma1
FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion	Erdafitinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID7261 Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC) Open in CIViC	civic

Transitional Cell Carcinoma1

FGFR2 Mutation OR FGFR2::v Fusion OR FGFR2::? Fusion

Erdafitinib

Predictive

Supports Sensitivity Response

accepted

EID7261

Patients with metastatic or unresectable urothelial carcinoma havoring FGFR2 fusion, FGFR3 fusion or FGFR3 mutation were treated with pan-FGFR inhibitor, erdafitinib, in Phase 2 trial. 96 patients wer… (full text at CIViC)

Open in CIViC

civic

Evidence by cancer (12 items)

Clinical significance (0)